Author: Editor

Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…

Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…

James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…

James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…

Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.

Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.

Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…

Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…

Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…

Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…

Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…

Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…

Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…

Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…

Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…

Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…

Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…

Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…

Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…

Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…

Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…

Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…

Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…

Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…

Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?

Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?

Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…

Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…

Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…

Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…

Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos Clínicos. Para este video, los doctores Velázquez y Franco analizan por qué debería participar en un ensayo clínico y cómo. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ********************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our Spanish-speaking community on Clinical Trials.…

¿Qué son los estudios clínicos? What are Clinical Trials? Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos Clínicos. Para este video, los doctores Velázquez y Franco analizan exactamente qué es un ensayo clínico. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ******************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the cost of clinical trials, billing practices, emergency treatment, and other expenses. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discussclinical trials and provisions or resources for stress and mental health. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what happens if you have to leave a clinical trial. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss if a trial could be the right fit even if your doctor doesn’t know about it. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss potential side effects you might expect on a clinical trial and how you manage them. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how being on a clinical trial can potentially impact your daily life. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss eligibility for clinical trials. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what a ‘first-in-human’ trial means, and whether participants are a ‘guinea pig’. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss placebos and their use in phase 1 clinical trials, and how it differs from other phases. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the phases of clinical trials and what they mean. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how medical data will be used and if it would be used without the participant’s knowledge. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss whether clinical trials are only for people who have no other options. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

¿Que es la radioterapia, cuando es utilizada, y cuales son los efectos secundarios más comunes?La Dra. Ivy Franco, participante en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tiene una discusión para nuestra comunidad de habla hispana sobre la radioterapia.Para este video, el Dr. Franco analiza qué es la radioterapia, cuándo se usa y cuáles son algunos de los efectos secundarios comunes.¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech!Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.************************************************************************Dr. Ivy Franco, a participant in this past year’s GRACE Patient Education Ambassador Program, has…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Antibody-Drug Conjugate Treatment Options #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lilly To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.